-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Pharmaceutical Network Industry Dynamics" into September, another group of pharmaceutical companies are keen to break through the IPO, including a spin-off subsidiary to the company listed on the board.
22nd, the IPO of Koxing Pharmaceuticals was submitted for registration, and the sponsor was CITIC Jian investment securities Co., Ltd.
the prospectine, the number of shares to be issued by Koxing Bio does not exceed 49.6753 million shares, and the proposed capital raising is about 1.7 billion yuan.
the company is expected to raise funds for drug production base expansion projects, research and development center upgrade construction projects, information management system upgrade construction projects and supplementary working capital.
is an innovative biopharmaceutical company specializing in the research, development, production and marketing of recombinant protein drugs and micro-ecological preparations.
At present, the company's main products include recombinant protein drugs "recombinant human erythroid", "recombinant human interferon alpha1b", "recombinant human granulocyte stimulation factor", micro-ecological preparation drug "Cytobacteria tyrosine."
Yuekang Pharmaceutical Co., D.C., september 15 news, Yuekang Pharmaceuticals Co., D.C., IPO meeting. according to the
prospectus, the company intends to issue no more than 90 million shares publicly and plans to raise 1.505 billion yuan for research and development center construction and innovative pharmaceutical research and development projects, solid preparations and small-capacity water needle preparations high-end production line construction projects, API technology upgrading projects, intelligent coding system construction projects, marketing center construction projects, intelligent plants and green upgrading projects and supplementary liquidity.
, the company's business is mainly focused on cardiovascular drugs, digestive drugs, diabetes drugs and anti-infective drugs and other fields.
nearly 10 months after the end of the listing review, Salem Bio intends to sprint again.
's path to listing, which had earlier landed on the new three boards in February 2016, was delisted in August 2017, a month after Salem Bio signed a listing counseling agreement with Shen Wanhongyuan to start the listing process, but ended the process on January 31, 2019.
On February 28, 2019, Salem Bio signed a coaching agreement with Haitong Securities and declared the company listed on the Board in May of that year, but after three rounds of inquiries, the listing process for Salem Bio was terminated.
documents on the Shanghai Stock Exchange show that the termination of the review was "due to the issuer withdrawing the listing application or the sponsor withdrawing the recommendation."
warner pharmaceutical company after the impact of the GEM failed, Warner Pharmaceuticals turned to the tablet.
information on the Shanghai Stock Exchange shows that Warner Pharmaceuticals' IPO has now entered the inquiry stage.
, it is understood that one of warner pharmaceutical company's fund-raising projects for an annual output of 1000 tons of high-end raw materials pharmaceutical production base construction project (phase I) continued.
specifically, the project mainly built three API production lines, a total annual output of 55 tons of products, including 10 tons of Trobenan sodium, 30 tons of zoonazine, 15 tons of hydrochloric acid citric acid.
the construction of the project, Warner Pharmaceuticals said that after the project is fully put into operation, it is expected to achieve sales revenue of 1 billion yuan, profit of 150 million yuan.
Tians Biotech has submitted an application for the listing of the Science and Trot board.
company plans to issue no more than 27.66 million shares, the funds raised will be used for innovative drug research and development projects, marketing and brand upgrading projects, supplementary liquidity.
it is understood that Tiansli is the controlling shareholder of Tiansi Bio, which held 87.75 per cent of the latter directly before the issue.
Tians Bio is an innovative biopharmaceian company, focusing on cardiovascular, tumor, autoimmune and digestive metabolism of these therapeutic areas.
company's revenue will decline in 2019.
believes that the spin-off of Tiansli bio-listing may help the latter broaden financing channels, increase investment in product research and development and increase operational independence.